Skip to content
  • Pipeline
    • SurVaxM
  • Clinical Trials
  • About
    • Leadership Team
  • News
  • Contact
Menu
  • Pipeline
    • SurVaxM
  • Clinical Trials
  • About
    • Leadership Team
  • News
  • Contact
Pipeline
SurVaxM
Clinical Trials
About
Leadership Team
News
Contact
Read more about the article Roswell Park Opens Phase 2B Randomized Clinical Trial of Promising Brain Cancer Immunotherapy

Roswell Park Opens Phase 2B Randomized Clinical Trial of Promising Brain Cancer Immunotherapy

  • Post author:mimivax
  • Post published:February 4, 2022
  • Post category:Uncategorized

First center to treat newly diagnosed glioblastoma patients as part of late-stage trial with SurVaxM BUFFALO, N.Y. — Roswell Park Comprehensive Cancer Center is the first center to treat patients…

Continue ReadingRoswell Park Opens Phase 2B Randomized Clinical Trial of Promising Brain Cancer Immunotherapy

Recent Posts

  • Roswell Park Opens Phase 2B Randomized Clinical Trial of Promising Brain Cancer Immunotherapy
  • MimiVax, LLC Receives FDA Approval to Initiate a New Phase 2b Clinical Study for the Treatment of Newly Diagnosed Glioblastoma
  • MimiVax Phase 2 study of SurVaxM in combination with pembrolizumab opens for recurrent glioblastoma patients.
  • MimiVax Advances Toward New Clinical Trial for Brain Cancer Immunotherapy SurVaxM
  • MimiVax LLC and Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. announce exclusive licensing agreement on SurVaxM for glioblastoma treatment in China

Recent Comments

    Archives

    • February 2022
    • November 2021
    • May 2020
    • November 2019
    • October 2019
    • May 2019
    • March 2018
    • August 2017
    • July 2016
    • September 2015
    • April 2015

    Categories

    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    MimiVax, LLC

    info@mimivax.com

    Elm & Carlton Streets
    Buffalo, NY 14263

    Back to top
    Twitter Linkedin Youtube